Published Date: 08 Mar 2023
Italy's biggest conglomerate, Intesa Sanpaolo, has paid 360 million euros ($382 million) in cash to acquire a 26.2% stake in health insurer Intesa Sanpaolo RBM Salute, which it does not own. that it will be used.
Read Full NewsSubcutaneous anifrolumab for SLE met its primary BICLA endpoint at 52 weeks and significantly increased DORIS-defined remission and low disease activity.
Stephanie Fradette, PharmD, head of neuromuscular development at Biogen, gave immediate reaction to the EC approval of high-dose nusinersen and its implications for evolving SMA treatment strategies.
A recent phase 2b study reveals mesdopetam's potential in reducing dyskinesia severity in Parkinson disease, despite no significant ON time improvement.
1.
Promising Results With Epcoritamab Monotherapy in Relapsed/Refractory CLL
2.
The biology of cancer as well as potential treatment options are examined by experts.
3.
Cancer patients with HIV have demonstrated safety with immune checkpoint inhibitors.
4.
Another KRAS Inhibitor Scores an Early Win in Advanced Non-Small Cell Lung Cancer
5.
In-person and Virtual Palliative Care Are Both Beneficial for Advanced Lung Cancer Patients.
1.
Harnessing Artificial Intelligence in Oncology: Innovations in Diagnosis, Treatment, and Patient Care
2.
Understanding Acute Myeloid Leukemia (AML) and Its Survival Rates
3.
Treating Oral Fibromas: Options and Guidelines for a Healthier Mouth
4.
The Danger of Methemoglobinemia and How to Prevent It
5.
Thyroid Cancer and Insulin Resistance: Unraveling the Complex Interplay for Better Patient Outcomes
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World
2.
Navigating the Complexities of Ph Negative ALL - Part VII
3.
Understanding the causes of anemia in adults beyond nutritional deficiencies
4.
A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months
5.
Should We Use DARA Up Front As First-Line Therapy in MM? - Part II
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation